SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Cheng-long Xie, Wen-Wen Wang, Su-fang Zhang, Jing Gan, Zhen-Guo Liu, Continuous dopaminergic stimulation (CDS)-based treatment in Parkinson's disease patients with motor complications: A systematic review and meta-analysis, Scientific Reports, 2014, 4,

    CrossRef

  2. 2
    Fabio Blandini, Marie-Therese Armentero, Dopamine receptor agonists for Parkinson's disease, Expert Opinion on Investigational Drugs, 2014, 23, 3, 387

    CrossRef

  3. 3
    I. Lettow, J. Röther, Pharmakotherapie des Morbus Parkinson beim älteren, multimorbiden Patienten, Der Internist, 2014, 55, 6, 728

    CrossRef

  4. 4
    R. Filippi, M. Rasetti, M. Lenzi, P. Bright, Possible effects of pramipexole on neck muscles in a patient with Parkinson's disease, Oxford Medical Case Reports, 2014, 2014, 1, 8

    CrossRef

  5. 5
    J. Kulisevsky, M.R. Luquin, J.M. Arbelo, J.A. Burguera, F. Carrillo, A. Castro, J. Chacón, P.J. García-Ruiz, E. Lezcano, P. Mir, J.C. Martinez-Castrillo, I. Martínez-Torres, V. Puente, Á. Sesar, F. Valldeoriola-Serra, R. Yañez, Advanced Parkinson's disease: Clinical characteristics and treatment. Part II, Neurología (English Edition), 2013, 28, 9, 558

    CrossRef

  6. 6
    Bernardo Dell’Osso, Terence A. Ketter, Laura Cremaschi, Gregorio Spagnolin, A. Carlo Altamura, Assessing the Roles of Stimulants/Stimulant-like Drugs and Dopamine-agonists in the Treatment of Bipolar Depression, Current Psychiatry Reports, 2013, 15, 8

    CrossRef

  7. 7
    Jose A. Franco-Chaves, Camilo F. Mateus, David A. Luckenbaugh, Pedro E. Martinez, Alan G. Mallinger, Carlos A. Zarate, Combining a dopamine agonist and selective serotonin reuptake inhibitor for the treatment of depression: A double-blind, randomized pilot study, Journal of Affective Disorders, 2013, 149, 1-3, 319

    CrossRef

  8. 8
    J. Kulisevsky, M.R. Luquin, J.M. Arbelo, J.A. Burguera, F. Carrillo, A. Castro, J. Chacón, P.J. García-Ruiz, E. Lezcano, P. Mir, J.C. Martinez-Castrillo, I. Martínez-Torres, V. Puente, Á. Sesar, F. Valldeoriola-Serra, R. Yañez, Enfermedad de Parkinson avanzada. Características clínicas y tratamiento. Parte II, Neurología, 2013, 28, 9, 558

    CrossRef

  9. 9
    Fabienne Sprenger, Werner Poewe, Management of Motor and Non-Motor Symptoms in Parkinson’s Disease, CNS Drugs, 2013, 27, 4, 259

    CrossRef

  10. 10
    Santiago Perez-Lloret, María Verónica Rey, Pietro Lucca Ratti, Olivier Rascol, Rotigotine transdermal patch for the treatment of Parkinson’s Disease, Fundamental & Clinical Pharmacology, 2013, 27, 1
  11. 11
    Peter A. LeWitt, Babak Boroojerdi, Erwin Surmann, Werner Poewe, Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson’s disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER, Journal of Neural Transmission, 2013, 120, 7, 1069

    CrossRef

  12. You have free access to this content12
    J. J. Ferreira, R. Katzenschlager, B. R. Bloem, U. Bonuccelli, D. Burn, G. Deuschl, E. Dietrichs, G. Fabbrini, A. Friedman, P. Kanovsky, V. Kostic, A. Nieuwboer, P. Odin, W. Poewe, O. Rascol, C. Sampaio, M. Schüpbach, E. Tolosa, C. Trenkwalder, A. Schapira, A. Berardelli, W. H. Oertel, Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease, European Journal of Neurology, 2013, 20, 1
  13. 13
    Valerie Suski, Mark Stacy, Handbook of Parkinson’s Disease, 2013,

    CrossRef

  14. 14
    Valerie Suski, Mark Stacy, Handbook of Parkinson's Disease, Fifth Edition, 2013,

    CrossRef

  15. 15
    Nicola Tambasco, Simone Simoni, Erica Marsili, Elisa Sacchini, Donatella Murasecco, Gabriela Cardaioli, Aroldo Rossi, Paolo Calabresi, Clinical Aspects and Management of Levodopa-Induced Dyskinesia, Parkinson's Disease, 2012, 2012, 1

    CrossRef

  16. 16
    John C. P. Piedad, Andrea E. Cavanna, Dyskinesias and Treatment with Pramipexole in Patients with Parkinson's Disease, Parkinson's Disease, 2012, 2012, 1

    CrossRef

  17. 17
    Lawrence W. Elmer, Erwin Surmann, Babak Boroojerdi, Joseph Jankovic, Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson’s disease: A prospective, open-label extension study, Parkinsonism & Related Disorders, 2012, 18, 5, 488

    CrossRef

  18. 18
    Thomas Müller, Manfred Gerlach, Moussa B.H. Youdim, Peter Riederer, Neurobiology of Psychiatric Disorders, 2012,

    CrossRef

  19. 19
    Rebecca Stowe, Natalie Ives, Carl E. Clarke, Kelly Handley, Alexandra Furmston, Katherine Deane, J.J. van Hilten, Keith Wheatley, Richard Gray, Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease, Movement Disorders, 2011, 26, 4
  20. 20
    Lawrence Elmer, Robert A Hauser, Strategies for Parkinson’s disease care: prevention and management of motor fluctuations, Neurodegenerative Disease Management, 2011, 1, 5, 415

    CrossRef

  21. 21
    Susan H. Fox, Regina Katzenschlager, Shen-Yang Lim, Bernard Ravina, Klaus Seppi, Miguel Coelho, Werner Poewe, Olivier Rascol, Christopher G. Goetz, Cristina Sampaio, The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease, Movement Disorders, 2011, 26, S3
  22. 22
    Albert F.G. Leentjens, The Role of Dopamine Agonists in the Treatment of Depression in Patients with Parkinsonʼs Disease, Drugs, 2011, 71, 3, 273

    CrossRef

  23. 23
    Santiago Perez-Lloret, Olivier Rascol, Dopamine Receptor Agonists for the Treatment of Early or Advanced Parkinsonʼs Disease, CNS Drugs, 2010, 24, 11, 941

    CrossRef

  24. 24
    Robert A. Hauser, Anthony H.V. Schapira, Olivier Rascol, Paolo Barone, Yoshikuni Mizuno, Laurence Salin, Monika Haaksma, Nolwenn Juhel, Werner Poewe, Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease, Movement Disorders, 2010, 25, 15
  25. 25
    Angelo Antonini, Paolo Barone, Roberto Ceravolo, Giovanni Fabbrini, Michele Tinazzi, Giovanni Abbruzzese, Role of Pramipexole in the Management of Parkinsonʼs Disease, CNS Drugs, 2010, 24, 10, 829

    CrossRef

  26. 26
    Jaime Kulisevsky, Javier Pagonabarraga, Tolerability and Safety of Ropinirole versus Other Dopamine Agonists and Levodopa in the Treatment of Parkinsonʼs Disease, Drug Safety, 2010, 33, 2, 147

    CrossRef

  27. 27
    Rodrigo CL Edelmuth, Michael A Nitsche, Linamara Battistella, Felipe Fregni, Why do some promising brain-stimulation devices fail the next steps of clinical development?, Expert Review of Medical Devices, 2010, 7, 1, 67

    CrossRef

  28. 28
    R. Talati, W. L. Baker, A. A. Patel, K. Reinhart, C. I. Coleman, Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson’s disease: a meta analysis, International Journal of Clinical Practice, 2009, 63, 4
  29. 29
    Chang-hai LIU, Qing-yan SUN, Chun-quan SHENG, Hai ZHANG, Jun CHEN, Liang ZHAO, Yi-feng CHAI, Capillary electrophoresis for analysis of optical impurity of L-pramipexole, Academic Journal of Second Military Medical University, 2009, 29, 9, 1058

    CrossRef

  30. 30
    Tapani Keränen, Mervi Tuhkasaari, Hanna Kuusisto, Long-term retention rate of pramipexole in the treatment of Parkinson’s disease, European Journal of Clinical Pharmacology, 2009, 65, 9, 955

    CrossRef

  31. 31
    Albert F.G. Leentjens, Jürgen Koester, Barbara Fruh, D. Toby S. Shephard, Paolo Barone, John J.G. Houben, The effect of pramipexole on mood and motivational symptoms in parkinson's disease: A meta-analysis of placebo-controlled studies, Clinical Therapeutics, 2009, 31, 1, 89

    CrossRef

  32. 32
    Maurits E. L. Arbouw, Kris L. L. Movig, Henk-Jan Guchelaar, Petra J. E. Poels, Jeroen P. P. Vugt, Cees Neef, Toine C. G. Egberts, Discontinuation of ropinirole and pramipexole in patients with Parkinson’s disease: clinical practice versus clinical trials, European Journal of Clinical Pharmacology, 2008, 64, 10, 1021

    CrossRef

  33. 33
    M. R. Lemke, Dopamine agonists in the treatment of non-motor symptoms of Parkinson’s disease: depression, European Journal of Neurology, 2008, 15,
  34. 34
    David A Gallagher, Anette Schrag, Impact of Newer Pharmacological Treatments on Quality of Life in Patients with Parkinson???s Disease, CNS Drugs, 2008, 22, 7, 563

    CrossRef

  35. 35
    Daniel D. Truong, Roongroj Bhidayasiri, Erik Wolters, Management of non-motor symptoms in advanced Parkinson disease, Journal of the Neurological Sciences, 2008, 266, 1-2, 216

    CrossRef

  36. 36
    Richard B. Dewey, Medical Management of Motor Fluctuations, Neurologic Clinics, 2008, 26, 3, 15

    CrossRef

  37. 37
    J. Kulisevsky, J. Pagonabarraga, B. Pascual-Sedano, A. Gironell, C. García-Sánchez, M. Martínez-Corral, Motor changes during sertraline treatment in depressed patients with Parkinson’s disease, European Journal of Neurology, 2008, 15, 9
  38. 38
    Andrew M. Farrar, Mariana Pereira, Francisco Velasco, Jörg Hockemeyer, Christa E. Müller, John D. Salamone, Adenosine A2A receptor antagonism reverses the effects of dopamine receptor antagonism on instrumental output and effort-related choice in the rat: implications for studies of psychomotor slowing, Psychopharmacology, 2007, 191, 3, 579

    CrossRef

  39. 39
    Robert A. Hauser, Theresa A. Zesiewicz, Advances in the Pharmacologic Management of Early Parkinson Disease, The Neurologist, 2007, 13, 3, 126

    CrossRef

  40. 40
    Pramipexole in Levodopa-treated Parkinson Disease Patients of African, Asian, and Hispanic Heritage, Clinical Neuropharmacology, 2007, 30, 2, 72

    CrossRef

  41. 41
    William G. Ondo, Kapil D. Sethi, Greg Kricorian, Selegiline Orally Disintegrating Tablets in Patients With Parkinson Disease and "Wearing Off" Symptoms, Clinical Neuropharmacology, 2007, 30, 5, 295

    CrossRef

  42. 42
    Willi Cawello, Hans Michael Wolff, Wim J A Meuling, Rolf Horstmann, Marina Braun, Transdermal Administration of Radiolabelled [14C]Rotigotine by a Patch Formulation, Clinical Pharmacokinetics, 2007, 46, 10, 851

    CrossRef

  43. 43
    Trond Kvernmo, Sebastian Härtter, Erich Burger, A review of the receptor-binding and pharmacokinetic properties of dopamine agonists, Clinical Therapeutics, 2006, 28, 8, 1065

    CrossRef

  44. 44
    John C Morgan, Kapil D Sethi, Emerging drugs for Parkinson’s disease, Expert Opinion on Emerging Drugs, 2006, 11, 3, 403

    CrossRef

  45. 45
    Anette Schrag, Quality of life and depression in Parkinson's disease, Journal of the Neurological Sciences, 2006, 248, 1-2, 151

    CrossRef

  46. 46
    M. Horstink, E. Tolosa, U. Bonuccelli, G. Deuschl, A. Friedman, P. Kanovsky, J. P. Larsen, A. Lees, W. Oertel, W. Poewe, O. Rascol, C. Sampaio, Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society–European Section. Part I: early (uncomplicated) Parkinson's disease, European Journal of Neurology, 2006, 13, 11
  47. 47
    F Fumagalli, G Racagni, M A Riva, Shedding light into the role of BDNF in the pharmacotherapy of Parkinson's disease, The Pharmacogenomics Journal, 2006, 6, 2, 95

    CrossRef

  48. 48
    Alan Diamond, Joseph Jankovic, Treatment of advanced Parkinson’s disease, Expert Review of Neurotherapeutics, 2006, 6, 8, 1181

    CrossRef

  49. 49
    Current awareness: Pharmacoepidemiology and drug safety, Pharmacoepidemiology and Drug Safety, 2005, 14, 11
  50. 50
    J Carsten Möller, Wolfgang H Oertel, Pramipexole in the treatment of Parkinson’s disease: new developments, Expert Review of Neurotherapeutics, 2005, 5, 5, 581

    CrossRef

  51. 51
    W. H. Oertel, A. Berardelli, B. R. Bloem, U. Bonuccelli, D. Burn, G. Deuschl, E. Dietrichs, G. Fabbrini, J. J. Ferreira, A. Friedman, P. Kanovsky, V. Kostic, A. Nieuwboer, P. Odin, W. Poewe, O. Rascol, C. Sampaio, M. Schüpbach, E. Tolosa, C. Trenkwalder, Early (Uncomplicated) Parkinson's Disease,
  52. 52
    Rebecca Stowe, Natalie Ives, Carl E Clarke, Katherine Deane, van Hilten, Keith Wheatley, Richard Gray, Kelly Handley, Alex Furmston, Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson´s disease patients with motor complications, The Cochrane Library,
  53. 53
    Miguel Coelho, Joaquim Ferreira, Cristina Sampaio, Parkinson's Disease,